Adverum Biotechnologies
ADVM
ADVM was delisted on the 8th of December, 2025.
141 hedge funds and large institutions have $1.69B invested in Adverum Biotechnologies in 2020 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 59 increasing their positions, 38 reducing their positions, and 14 closing their positions.
211% more call options, than puts
Call options by funds: $15.9M | Put options by funds: $5.1M
116% more capital invested
Capital invested by funds: $782M → $1.69B (+$906M)
107% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 14
55% more repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 38
14% more funds holding in top 10
Funds holding in top 10: 7 → 8 (+1)
12% more funds holding
Funds holding: 126 → 141 (+15)
0.28% more ownership
Funds ownership: 100.44% → 100.71% (+0.28%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$22M |
| 2 |
BlackRock
New York
|
+$15.3M |
| 3 |
CC
Casdin Capital
New York
|
+$13.1M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$11.8M |
| 5 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$9.37M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$23M |
| 2 |
DM
Deerfield Management
New York
|
-$22M |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$14.4M |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
-$11.7M |
| 5 |
VA
VR Adviser
New York
|
-$9.71M |
ADVM Hedge Fund Activity: Q2 2020 in Review
141 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in Adverum Biotechnologies (ADVM) for Q2 2020, worth a combined $1.69B — up 116% from $782M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new ADVM positions and 14 closed out — a net gain of 15 holders — while 59 added to existing stakes and 38 trimmed.
The largest buyer was Wellington Management Group, opening a new position worth an estimated $22M. The largest seller was Adage Capital Partners, cutting an estimated $23M.
- 141 institutional investors held Adverum Biotechnologies (ADVM) as of Q2 2020, up from 126 in Q1 2020.
- Funds reported $1.69B of Adverum Biotechnologies stock for Q2 2020, up 116% quarter-over-quarter.
- 29 funds opened new Adverum Biotechnologies positions in Q2 2020 and 14 closed out, a net change of +15 holders.
- The largest Adverum Biotechnologies buyer in Q2 2020 was Wellington Management Group, an estimated $22M added.
- The largest Adverum Biotechnologies seller in Q2 2020 was Adage Capital Partners, an estimated $23M sold.
Based on aggregated 13F filings for Q2 2020.